JP2022548145A5 - - Google Patents

Info

Publication number
JP2022548145A5
JP2022548145A5 JP2022517139A JP2022517139A JP2022548145A5 JP 2022548145 A5 JP2022548145 A5 JP 2022548145A5 JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022548145 A5 JP2022548145 A5 JP 2022548145A5
Authority
JP
Japan
Prior art keywords
compound according
pharmaceutical composition
domain
cell
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548145A (ja
JP7773152B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050851 external-priority patent/WO2021055342A1/en
Publication of JP2022548145A publication Critical patent/JP2022548145A/ja
Publication of JP2022548145A5 publication Critical patent/JP2022548145A5/ja
Priority to JP2025182211A priority Critical patent/JP2026021424A/ja
Application granted granted Critical
Publication of JP7773152B2 publication Critical patent/JP7773152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517139A 2019-09-16 2020-09-15 免疫療法の化合物および方法 Active JP7773152B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182211A JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901,198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182211A Division JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Publications (3)

Publication Number Publication Date
JP2022548145A JP2022548145A (ja) 2022-11-16
JP2022548145A5 true JP2022548145A5 (https=) 2023-09-21
JP7773152B2 JP7773152B2 (ja) 2025-11-19

Family

ID=74883667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517139A Active JP7773152B2 (ja) 2019-09-16 2020-09-15 免疫療法の化合物および方法
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Country Status (10)

Country Link
US (1) US20220324972A1 (https=)
EP (1) EP4031565A4 (https=)
JP (2) JP7773152B2 (https=)
KR (1) KR20220087441A (https=)
CN (1) CN115023435B (https=)
AU (1) AU2020350524A1 (https=)
BR (1) BR112022004712A2 (https=)
CA (1) CA3154158A1 (https=)
IL (1) IL291343A (https=)
WO (1) WO2021055342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR20240067088A (ko) * 2021-09-16 2024-05-16 지티 바이오파마, 인크. 융합 단백질을 표적으로 하는 pd-l1 및 이의 사용 방법
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2015DN01299A (https=) * 2012-07-23 2015-07-03 Zymeworks Inc
CA2924398A1 (en) * 2013-11-05 2015-05-14 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
EP3322735A4 (en) * 2015-07-15 2019-03-13 Zymeworks Inc. ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Similar Documents

Publication Publication Date Title
JP2022505158A5 (https=)
US11512128B2 (en) VEGF/DLL4 binding agents and uses thereof
JP7308041B2 (ja) 多重特異性抗原結合分子およびその使用
EP3319994B1 (en) Multispecific antigen-binding molecules and uses thereof
JP2022548145A5 (https=)
ES2719495T3 (es) Anticuerpo dirigido contra b7-h6, proteínas de fusión, y métodos de uso de los mismos
JP2026035673A (ja) 抗ｈｅｒ２抗体－薬物コンジュゲート投与による耐性癌の治療
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
KR102255616B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
Groner et al. Therapeutic antibodies
JP2021510736A5 (https=)
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
US11407841B2 (en) Recombinant bi-functional fusion protein and use thereof
JP2010504755A5 (https=)
CN104768579A (zh) 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
JP2023544143A5 (https=)
JP2022534724A5 (https=)
CN103417965A (zh) 一种含有抗vegf抗体的药物组合物
RU2021113936A (ru) Вовлекающие nk молекулы и способы их применения
KR101927732B1 (ko) ＥｒｂＢ3에 특이적으로 결합하는 항체를 포함하는 항암제 내성 암의 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
US20240360246A1 (en) Antibodies against ykl-40 and uses thereof
CA3165685C (en) Tandem repeat cancer-targeting peptides for molecular conjugation or engineering and uses thereof in cancer theranostics
Guilleminault et al. Monoclonal antibodies: An emerging class of therapeutics in non small cell lung cancer
AU2017210673A1 (en) VEGF/DLL4 binding agents and uses thereof
Kiprijanov Bispecific antibodies and immune therapy targeting